Drug Management of Prostate Cancer

DESCRIZIONE

This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry.Table of contents Section One Hormone Therapy Chapter 1 Cell Biology of Prostate Cancer and Molecular Targets Martin E. Gleave, Michael E. Cox, Yuzhuo Wang Chapter 2 Luteinizing Hormone-Releasing Hormone (Lh-Rh) and its Agnostic, Antagonistic and Targeted Cytotoxic Analogs in Prostate Cancer Andrew V. Schally and Norman L. Block Chapter 3 Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer Hannelore V. Heemers and Donald J. Tindall Chapter 4 Androgens and Prostate Cancer Douglas K. Price and Ann W. Hsing Chapter 5 Androgen Receptor Biology in Prostate Cancer Edward P. Gelmann Chapter 6 Androgen Receptor Antagonists Howard C. Shen, Mary-Ellen Taplin, Steven P. Balk Chapter 7 5 alpha Reductase Inhibitors in Prostate Cancer Zoran Culig Chapter 8 Adrenolytic Therapies in Castration Resistant Prostate Cancer Terence W. Friedlander and Charles J. Ryan Chapter 9 Androgen Deprivation Therapy Nima Sharifi Chapter 10 Pharmacogenetics of the Androgen Metabolic Pathway Francine Zanchetta Coehlo Marques and Juergen Reichardt Section Two Chemotherapy Chapter 11 Mitoxantrone Patricia Halterman, Nicholas J. Vogelzang, Alireza Farabishahadel, Oscar B. Goodman, Jr. Chapter 12 Docetaxel Courtney K. Phillips and Daniel P. Petrylak Chapter 13 Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer Jonathan Rosenberg Chapter 14 Platinum Agents in Prostate Cancer Ashley Brick, Junyang Niu, Jiaoti Huang, William K. Oh Chapter 15 Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer Tristan M. Sissung and William D. Figg Chapter 16 Microtubule Targeting Agents Antonio Tito Fojo and David E. Adelberg Section Three Angiogenesis Chapter 17 Principles of Antiangiogenic Therapy Cindy H. Chau and William D. Figg Chapter 18 Bevacizumab in Advanced Prostate Cancer Aymen A. Elfiky and William Kevin Kelly Chapter 19 Thalidomide and Analogs Erin R. Gardner, Giuseppe Di Lorenzo, and William D. Figg Chapter 20 Investigational Angiogenesis Inhibitors Jeanny B. Aragon-Ching, William Dahut, MD Chapter 21 Pharmacogenetics of Angiogenesis Guido Bocci, Giuseppe Pasqualetti, Antonello Di Paolo, Francesco Crea, Mario Del Tacca, Romano Danesi Section Four Bone Metastasis Chapter 22 Pathophysiology of Prostate Cancer Bone Metastasis Evan T. Keller and Christopher L. Hall Chapter 23 Radiopharmaceuticals Oliver Sartor and Damerla R. Venugopal Chapter 24 Bisphosphonates for Prevention and Treatment of Bone Metastases Philip J. Saylor and Matthew R. Smith Chapter 25 Endothelin Receptors as Therapeutic Targets in Castrate Resistant Prostate Cancer Joel B. Nelson Chapter 26 Calcitriol and Vitamin D Analogs Ana R. Jensen, Russell Z. Szmulewitz, Tomasz M. Beer, Edwin M. Posadas Chapter 27 Cancer Immunology, Immunotherapeutics and Vaccine Approaches Ravi A. Madan, James L. Gulley, Jackie Celestin, Philip M. Arlen, Jeffrey Schlom Chapter 28 Sipuleucel-T (APC8015): Active Cellular Immunotherapy for Advanced Metastatic Castrate-Resistant Prostate Cancer Celestia S. Higano and Mark W. Frohlich Chapter 29 GM-CSF Genes Transduced Prostate Cancer Vaccines: GVAX Lalit R. Patel and Jonathan W. Simons Chapter 30 CTLA-4 Blockade for Prostate Cancer Treatment Andrea L. Harzstark and Lawrence Fong Section Five – Prevention Chapter 31 Prostate Cancer Chemoprevention Strategies Howard L. Parnes, Margaret G. House, Joseph A. Tangrea Chapter 32 Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk June M. Chan and Erin L. Richman Chapter 33 Inflammation as a Target in Prostate Cancer Marshall Scott Lucia, James R. Lambert, Elizabeth A. Platz, Angelo M. De Marzo Section Six Drug Development Chapter 34 Challenges for the Development of New Agents in Prostate Cancer Ajjai S. Alva, Deborah A. Bradley, Maha Hussain Chapter 35 FDA Approval of Prostate Cancer Treatments Yang-Min Ning, Ramzi N. Dagher, Richard Pazdur Chapter 36 Applications of Proteomics in Prostate Cancer Mitchell Gross, Edward Macrohon Nepomuceno, David B. Agus

DETTAGLI PRODOTTO  torna su

ISBN: 9781603278317

Titolo: Drug Management of Prostate Cancer

Autori: Figg - Chau - Small

Editore: Springer Verlag

Volume: Unico

Edizione: 2010

Lingua: Inglese

Finitura: Copertina rigida

Pagine: 698

RECENSIONI

NESSUNA RECENSIONE PER QUESTO PRODOTTO